Treace Medical Concepts (TMCI) Competitors $7.46 -0.24 (-3.05%) As of 03:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TMCI vs. ENOV, CNMD, NVCR, SSII, CDRE, BLFS, ESTA, PLSE, MDXG, and INMDShould you be buying Treace Medical Concepts stock or one of its competitors? The main competitors of Treace Medical Concepts include Enovis (ENOV), CONMED (CNMD), NovoCure (NVCR), SS Innovations International (SSII), Cadre (CDRE), BioLife Solutions (BLFS), Establishment Labs (ESTA), Pulse Biosciences (PLSE), MiMedx Group (MDXG), and InMode (INMD). These companies are all part of the "medical equipment" industry. Treace Medical Concepts vs. Its Competitors Enovis CONMED NovoCure SS Innovations International Cadre BioLife Solutions Establishment Labs Pulse Biosciences MiMedx Group InMode Treace Medical Concepts (NASDAQ:TMCI) and Enovis (NYSE:ENOV) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability. Do analysts recommend TMCI or ENOV? Treace Medical Concepts presently has a consensus target price of $9.83, suggesting a potential upside of 31.73%. Enovis has a consensus target price of $51.00, suggesting a potential upside of 64.57%. Given Enovis' stronger consensus rating and higher probable upside, analysts clearly believe Enovis is more favorable than Treace Medical Concepts.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Treace Medical Concepts 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Enovis 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer TMCI or ENOV? In the previous week, Enovis had 9 more articles in the media than Treace Medical Concepts. MarketBeat recorded 10 mentions for Enovis and 1 mentions for Treace Medical Concepts. Treace Medical Concepts' average media sentiment score of 1.67 beat Enovis' score of 1.45 indicating that Treace Medical Concepts is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Treace Medical Concepts 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Enovis 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, TMCI or ENOV? Treace Medical Concepts has higher earnings, but lower revenue than Enovis. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTreace Medical Concepts$209.36M2.25-$55.74M-$0.79-9.45Enovis$2.11B0.84-$825.49M-$14.25-2.17 Which has more volatility and risk, TMCI or ENOV? Treace Medical Concepts has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Enovis has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500. Is TMCI or ENOV more profitable? Treace Medical Concepts has a net margin of -23.01% compared to Enovis' net margin of -37.80%. Enovis' return on equity of 6.78% beat Treace Medical Concepts' return on equity.Company Net Margins Return on Equity Return on Assets Treace Medical Concepts-23.01% -46.76% -23.35% Enovis -37.80%6.78%3.73% Do institutionals & insiders hold more shares of TMCI or ENOV? 84.1% of Treace Medical Concepts shares are held by institutional investors. Comparatively, 98.5% of Enovis shares are held by institutional investors. 27.7% of Treace Medical Concepts shares are held by company insiders. Comparatively, 2.7% of Enovis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryEnovis beats Treace Medical Concepts on 10 of the 16 factors compared between the two stocks. Get Treace Medical Concepts News Delivered to You Automatically Sign up to receive the latest news and ratings for TMCI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TMCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TMCI vs. The Competition Export to ExcelMetricTreace Medical ConceptsMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$470.93M$6.94B$5.76B$9.75BDividend YieldN/A1.29%4.40%4.10%P/E Ratio-9.4427.0930.8325.91Price / Sales2.2560.49469.77121.46Price / CashN/A22.3525.7828.79Price / Book4.124.889.466.03Net Income-$55.74M$176.42M$3.27B$265.29M7 Day Performance6.04%0.18%2.37%2.86%1 Month Performance30.96%-2.49%3.88%1.23%1 Year Performance16.28%9.86%30.52%19.11% Treace Medical Concepts Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TMCITreace Medical Concepts2.5689 of 5 stars$7.47-3.1%$9.83+31.7%+19.9%$470.93M$209.36M-9.44250Positive NewsENOVEnovis4.4797 of 5 stars$29.51-0.1%$51.00+72.8%-31.8%$1.69B$2.11B-2.077,367Positive NewsInsider TradeCNMDCONMED3.9401 of 5 stars$53.35+0.4%$59.80+12.1%-22.4%$1.64B$1.31B15.113,900Positive NewsNVCRNovoCure4.1746 of 5 stars$12.09+3.1%$28.79+138.1%-31.0%$1.31B$605.22M-7.751,488SSIISS Innovations InternationalN/A$6.55-2.1%N/AN/A$1.30B$20.65M0.004Gap DownCDRECadre1.9373 of 5 stars$29.66+1.4%$31.50+6.2%-13.9%$1.19B$567.56M31.552,284Positive NewsBLFSBioLife Solutions2.6581 of 5 stars$24.50+0.7%$31.29+27.7%+2.4%$1.17B$82.25M-204.15440Positive NewsESTAEstablishment Labs1.8664 of 5 stars$38.25-0.2%$55.80+45.9%-4.4%$1.11B$166.02M-12.541,018Positive NewsPLSEPulse Biosciences2.7702 of 5 stars$15.68-3.0%$22.00+40.3%-20.6%$1.09B$700K-14.93140MDXGMiMedx Group3.2247 of 5 stars$7.19+1.1%$12.00+66.9%+5.9%$1.05B$348.88M34.24870Positive NewsINMDInMode1.9399 of 5 stars$14.31-0.3%$18.04+26.1%-8.9%$907.05M$394.82M5.79480News CoveragePositive News Related Companies and Tools Related Companies Enovis Alternatives CONMED Alternatives NovoCure Alternatives SS Innovations International Alternatives Cadre Alternatives BioLife Solutions Alternatives Establishment Labs Alternatives Pulse Biosciences Alternatives MiMedx Group Alternatives InMode Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TMCI) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Treace Medical Concepts, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Treace Medical Concepts With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access